Vitamin E Supplementation for Mild-to-Moderate Alzheimer Disease

A modest benefit was noted in a 2-year randomized trial.

In a previous study of patients with moderately severe Alzheimer disease, high-dose vitamin E supplementation (2000 IU daily) conferred modest benefit that was reflected mainly in fewer patients requiring institutionalization and slower decline in performing activities of daily living (ADLs; NEJM JW Womens Health May 1 1997). Now, in a placebo-controlled, randomized trial, 613 U.S. veterans (nearly all men) with mild-to-moderate Alzheimer disease received vitamin E (2000 IU daily), memantine (Namenda), both, or neither. All patients were taking an acetylcholinesterase inhibitor at time of enrollment.

The primary outcome was decline in a 78-point ADL score (mean baseline score, 57). During an average follow-up of 2.3 years, the decline was si…

Reviewing Author

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Vitamin E Supplementation for Mild-to-Moderate Alzheimer Disease

Topics

Reviewing Author